Kidney disease in very long-term survivors of Wilms tumor: A nationwide cohort study with sibling controls.
Wilms tumor
chronic kidney disease
late effects
survivorship
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
14
04
2022
received:
08
12
2021
accepted:
30
06
2022
pubmed:
17
7
2022
medline:
1
2
2023
entrez:
16
7
2022
Statut:
ppublish
Résumé
Survival after Wilms tumor has significantly increased and focus on late effects has become increasingly important. However, knowledge about long-term renal function in survivors of Wilms tumor is missing. Our aim was to investigate evidence of kidney disease in 20- or more-year survivors of Wilms tumor in a clinical setting, with siblings as comparisons. In this cross-sectional study, we established a cohort of Danish 20-plus-year survivors of Wilms tumor and siblings as controls. Participants answered a comprehensive health questionnaire supplemented by measurements of estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio, and blood pressure and were categorized according to the chronic kidney disease classification. Multiple linear regression analysis, taking family membership into account, was used to describe the differences in eGFR. Logistic regression analysis was performed to describe risk factors for the development of kidney disease. We included 99 survivors of Wilms tumor and 38 sibling controls with a median of 37 years of follow-up. The eGFR of Wilms tumor survivors was 13 ml/min/1.73 m Long-term Wilms tumor survivors have on average a significantly decreased renal function along with the increased prevalence of kidney disease and end-stage renal disease when compared to sibling controls. Still, most survivors had kidney function within the normal range.
Sections du résumé
BACKGROUND
Survival after Wilms tumor has significantly increased and focus on late effects has become increasingly important. However, knowledge about long-term renal function in survivors of Wilms tumor is missing. Our aim was to investigate evidence of kidney disease in 20- or more-year survivors of Wilms tumor in a clinical setting, with siblings as comparisons.
METHODS
In this cross-sectional study, we established a cohort of Danish 20-plus-year survivors of Wilms tumor and siblings as controls. Participants answered a comprehensive health questionnaire supplemented by measurements of estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio, and blood pressure and were categorized according to the chronic kidney disease classification. Multiple linear regression analysis, taking family membership into account, was used to describe the differences in eGFR. Logistic regression analysis was performed to describe risk factors for the development of kidney disease.
RESULTS
We included 99 survivors of Wilms tumor and 38 sibling controls with a median of 37 years of follow-up. The eGFR of Wilms tumor survivors was 13 ml/min/1.73 m
CONCLUSION
Long-term Wilms tumor survivors have on average a significantly decreased renal function along with the increased prevalence of kidney disease and end-stage renal disease when compared to sibling controls. Still, most survivors had kidney function within the normal range.
Identifiants
pubmed: 35841204
doi: 10.1002/cam4.5010
pmc: PMC9883410
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1330-1338Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Clin Res Cardiol. 2008 May;97(5):318-26
pubmed: 18193371
Nephrol Dial Transplant. 2017 Feb 1;32(2):348-355
pubmed: 28031344
Pediatr Blood Cancer. 2014 Sep;61(9):1638-43
pubmed: 24760750
Pediatr Hematol Oncol. 2009 Sep;26(6):407-13
pubmed: 19657990
Pediatr Blood Cancer. 2015 Sep;62(9):1637-44
pubmed: 25893525
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Eur J Cancer. 2012 Nov;48(17):3249-56
pubmed: 22796116
J Pediatr Surg. 2017 Jan;52(1):98-103
pubmed: 27856008
Pediatr Blood Cancer. 2021 May;68(5):e28905
pubmed: 33484071
Pediatr Blood Cancer. 2011 Dec 15;57(7):1210-6
pubmed: 21384541
Med Pediatr Oncol. 1993;21(3):172-81
pubmed: 7680412
Pediatr Nephrol. 2011 May;26(5):759-66
pubmed: 21279390
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
pubmed: 16514137
Expert Rev Anticancer Ther. 2006 Feb;6(2):249-58
pubmed: 16445377
Cancer Med. 2023 Jan;12(2):1330-1338
pubmed: 35841204
J Urol. 2005 Nov;174(5):1972-5
pubmed: 16217371
Med Pediatr Oncol. 2002 Apr;38(4):229-39
pubmed: 11920786
J Clin Oncol. 2016 May 20;34(15):1772-9
pubmed: 27022116
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
J Clin Oncol. 2009 Mar 10;27(8):1304-9
pubmed: 19139431
J Clin Oncol. 2004 Apr 15;22(8):1366-72
pubmed: 15084612
Pediatr Blood Cancer. 2020 Oct;67(10):e28271
pubmed: 32706494
Eur J Cancer. 1996 Mar;32A(3):465-9
pubmed: 8814694
Clin J Am Soc Nephrol. 2012 Sep;7(9):1416-27
pubmed: 22822016
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1736-46
pubmed: 24064520
Curr Opin Pediatr. 2009 Jun;21(3):357-64
pubmed: 19417665
Eur J Cancer. 2021 Sep;155:216-226
pubmed: 34391054
Pediatr Blood Cancer. 2015 Dec;62(12):2204-10
pubmed: 26193842
Ann Oncol. 2012 Sep;23(9):2457-2463
pubmed: 22415585
J Urol. 2011 Aug;186(2):378-86
pubmed: 21683387
Oncologist. 2005 Nov-Dec;10(10):815-26
pubmed: 16314292
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715